MRA Advisory Group Sells 5,659 Shares of AbbVie Inc. $ABBV

MRA Advisory Group lessened its holdings in AbbVie Inc. (NYSE:ABBV) by 71.8% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 2,224 shares of the company’s stock after selling 5,659 shares during the period. MRA Advisory Group’s holdings in AbbVie were worth $582,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. PFW Advisors LLC boosted its position in shares of AbbVie by 5.4% during the 3rd quarter. PFW Advisors LLC now owns 917 shares of the company’s stock valued at $240,000 after acquiring an additional 47 shares in the last quarter. Worth Asset Management LLC raised its position in AbbVie by 87.9% in the third quarter. Worth Asset Management LLC now owns 3,501 shares of the company’s stock worth $916,000 after purchasing an additional 1,638 shares in the last quarter. Matrix Trust Co lifted its stake in AbbVie by 7.1% during the third quarter. Matrix Trust Co now owns 13,447 shares of the company’s stock worth $3,518,000 after purchasing an additional 892 shares during the period. Crumly & Associates Inc. lifted its stake in AbbVie by 39.0% during the third quarter. Crumly & Associates Inc. now owns 3,927 shares of the company’s stock worth $1,027,000 after purchasing an additional 1,102 shares during the period. Finally, First Community Trust NA boosted its holdings in AbbVie by 9.1% during the third quarter. First Community Trust NA now owns 13,252 shares of the company’s stock valued at $3,467,000 after purchasing an additional 1,106 shares in the last quarter. 70.23% of the stock is owned by institutional investors.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Major lymphoma trial success: AbbVie and Genmab reported that Epkinly (epcoritamab) combined with R-CHOP reduced the risk of disease progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma (DLBCL). The Phase 3 EPCORE DLBCL-2 study achieved its progression-free-survival goal, potentially positioning Epkinly as a frontline treatment competitor to Roche’s Polivy. The companies plan to discuss the results with regulators. AbbVie and Genmab announce positive EPCORE DLBCL-2 results
• Positive Sentiment: Two FDA breakthrough designations: The FDA granted Temab-A (telisotuzumab adizutecan, or ABBV-400) Breakthrough Therapy Designations for colorectal cancer and non-small cell lung cancer. The designations may accelerate regulatory interactions and improve the commercial outlook for AbbVie’s antibody-drug-conjugate pipeline. AbbVie Temab-A FDA breakthrough designations
• Positive Sentiment: Higher valuation support: Scotiabank raised its AbbVie price target from $280 to $320 and maintained a “sector outperform” rating. The target increase reflects confidence in the company’s pipeline and earnings durability.
• Neutral Sentiment: Upcoming earnings catalyst: Investors are looking ahead to AbbVie’s third-quarter results later this month, which could provide additional evidence on operating performance and the company’s post-Humira growth strategy.
• Negative Sentiment: Lower near-term EPS guidance: AbbVie included $216 million of acquired in-process research and development and milestone expenses in its third-quarter outlook, resulting in EPS guidance of $3.73–$3.77 versus the prior consensus estimate of approximately $3.85. Full-year adjusted EPS guidance was also reduced.
• Negative Sentiment: Dividend sustainability concerns: Recent commentary highlighted a reported payout ratio above 190%, raising questions about how comfortably current earnings cover the dividend. This could limit enthusiasm among income-focused investors despite AbbVie’s strong pipeline news.

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.06% of the company’s stock.

AbbVie Stock Up 2.6%

ABBV traded up $6.97 during trading on Wednesday, hitting $273.66. The company’s stock had a trading volume of 2,122,512 shares, compared to its average volume of 6,413,482. The stock has a market capitalization of $483.50 billion, a price-to-earnings ratio of 77.32, a price-to-earnings-growth ratio of 1.20 and a beta of 0.24. The firm’s 50 day moving average price is $258.12 and its two-hundred day moving average price is $235.42. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $274.94.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company had revenue of $16.99 billion for the quarter, compared to analysts’ expectations of $16.80 billion. During the same quarter in the prior year, the business earned $2.97 earnings per share. The business’s revenue for the quarter was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, sell-side analysts forecast that AbbVie Inc. will post 14.05 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 2.5%. The ex-dividend date is Thursday, October 15th. AbbVie’s dividend payout ratio (DPR) is presently 195.48%.

Wall Street Analyst Weigh In

ABBV has been the subject of a number of recent research reports. UBS Group reissued a “neutral” rating on shares of AbbVie in a report on Tuesday. Bank of America reaffirmed a “buy” rating on shares of AbbVie in a research note on Tuesday, September 8th. Sanford C. Bernstein reiterated a “market perform” rating and set a $225.00 price objective (up from $203.00) on shares of AbbVie in a research note on Tuesday, June 23rd. BNP Paribas Exane lifted their price objective on AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a report on Tuesday, August 11th. Finally, Piper Sandler boosted their target price on shares of AbbVie from $298.00 to $303.00 and gave the company an “overweight” rating in a research note on Thursday, August 20th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $274.32.

AbbVie Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.